<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01878526</url>
  </required_header>
  <id_info>
    <org_study_id>GERD therapy in scleroderma</org_study_id>
    <secondary_id>PPI in SSc-GERD</secondary_id>
    <nct_id>NCT01878526</nct_id>
  </id_info>
  <brief_title>Gastroesophageal Reflux Treatment in Scleroderma</brief_title>
  <acronym>GERD-SSc</acronym>
  <official_title>The Effectiveness of Domperidone Versus Alginic Acid Add on Omeprazole Therapy in Omeprazole Resistance Gastroesophageal Reflux in Systemic Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Khon Kaen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Khon Kaen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators purposes are to define the prevalence of omeprazole resistance
      gastroesophageal reflux disease (GERD) in systemic sclerosis (SSc), to compare the efficacy
      of omeprazole in combination with algycon versus omeprazole in combination with domperidone
      on the severity of reflux symptoms in omeprazole resistant GERD in SSc, and to compare the
      efficacy of omeprazole in combination with algycon versus omeprazole in combination with
      domperidone on the frequency of symptoms in omeprazole- resistant GERD in SSc.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changing Severity of Heart Burn of SSc Related Omeprazole Resistant GERD Evaluated by Visual Analogue Score (VAS)</measure>
    <time_frame>8 weeks</time_frame>
    <description>VAS scale 0-100 was applied for an outcome measurement of the severity of heart burn. The VAS scale 0 was no symptoms of heart burn and scale 100 was a maximum symptom of heart burn. The changing of the severity of heart burn was the changing of VAS before and after treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changing of the Severity of Regurgitation</measure>
    <time_frame>8 weeks</time_frame>
    <description>VAS scale 0-100 was applied for an outcome measurement of the severity of regurgitation. The VAS scale 0 was no symptoms of regurgitation and scale 100 was a maximum symptom of regurgitation. The changing of the severity of regurgitation was the changing of VAS before and after treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changing of Frequency of Symptoms in SSc Related Omeprazole Resistant GERD Evaluated by Frequency Scale for the Symptoms of GERD (FSSG)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Unit scale 0-48 was applied for an outcome measurement of the frequency of symptoms. The unit scale 0 was no symptom and scale 48 was usual symptom of GERD. The changing of the frequency of symptoms was the changing of the unit scale before and after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Prevalence of Omeprazole-resistant GERD in SSc After 4 Weeks Treatment With Omeprazole</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changing of the Quality of Life Which is Evaluated by EQ-5DTM</measure>
    <time_frame>8 weeks</time_frame>
    <description>VAS scale 0-100 was applied for an outcome measurement of the quality of life. The VAS scale 0 was the worst quality of life and scale 100 was the best quality of life. The changing of the quality of life was the changing of VAS of quality of life before and after treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Gastroesophageal Reflux Disease</condition>
  <condition>Systemic Sclerosis</condition>
  <condition>Scleroderma</condition>
  <arm_group>
    <arm_group_label>Omeprazole plus alginic acid and placebo of domperidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Omeprazole plus domperidone and placebo of alginic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alginic acid</intervention_name>
    <description>Algycon 1 tab chew tid after meal</description>
    <arm_group_label>Omeprazole plus alginic acid and placebo of domperidone</arm_group_label>
    <other_name>Algycon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo (for domperidone)</intervention_name>
    <description>placebo (for domperidone) 1 tab oral tid before meal</description>
    <arm_group_label>Omeprazole plus alginic acid and placebo of domperidone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Domperidone</intervention_name>
    <description>domperidone (10 mg) 1 tab oral tid before meal</description>
    <arm_group_label>Omeprazole plus domperidone and placebo of alginic acid</arm_group_label>
    <other_name>Molax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo (of alginic acid)</intervention_name>
    <description>placebo (for alginic acid) 1 tab chew tid after meal</description>
    <arm_group_label>Omeprazole plus domperidone and placebo of alginic acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Phase 1 SSc patients who fit all inclusion and exclusion criteria will be eligible to phase
        1 study for evaluation the prevalence of omeprazole resistant-GERD

        Inclusion criteria:

          1. SSc patients aged between 18 and 65 years.

          2. Clinically diagnosed as GERD and GERD-questionnaire score &gt;3

          3. Must not receive any proton pump inhibitor (PPI) or prokinetic drug within 2 weeks
             before baseline evaluation

        Exclusion criteria:

          1. Pregnancy or lactation

          2. Previous history of gastroesophageal surgery or endoscopic therapy due to severe
             erosive esophagitis

          3. Present of Barrett's esophagus

          4. Bedridden and confined to no self-care

          5. Evidence of active malignant disease

          6. Present of uncontrolled or severe medical problems such as asthma, angina, hepatic or
             renal diseases

          7. Present of active infection that needs systemic antibiotic

          8. Allergic history of omeprazole

          9. Receiving prohibit co-medications that may have drug interaction or attenuate GERD
             symptoms such as tetracycline, ferrous salt, digoxin, isoniacid, oral bisphosphonate

        Phase 2 randomized parallel study SSc patients who fit all inclusion and exclusion criteria
        will be eligible to phase 2 study.

        Inclusion criteria:

          1. SSc patients who completed the phase 1 study.

          2. The subjects were defined as PPI-resistance.

          3. The subject must be willing to continue phase 2 study.

        Exclusion criteria:

          1. Pregnancy

          2. Present of uncontrolled or severe medical problems

          3. Present of active infection

          4. Allergic history of alginic acid or domperidone

          5. Receiving prohibit co-medications that may have drug interaction or attenuate GERD
             symptoms such as tetracycline, ferrous salt, digoxin, isoniacid, oral bisphosphonate

          6. Chewing difficulty
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chingching Foocharoen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>123 Department of Medicine, Faculty of Medicine, Khon Kaen University</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2013</study_first_submitted>
  <study_first_submitted_qc>June 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2013</study_first_posted>
  <results_first_submitted>August 22, 2016</results_first_submitted>
  <results_first_submitted_qc>February 3, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 27, 2017</results_first_posted>
  <last_update_submitted>February 3, 2017</last_update_submitted>
  <last_update_submitted_qc>February 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Khon Kaen University</investigator_affiliation>
    <investigator_full_name>Chingching Foocharoen</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>gastroesophageal reflux disease</keyword>
  <keyword>heart burn</keyword>
  <keyword>regurgitation</keyword>
  <keyword>systemic sclerosis</keyword>
  <keyword>scleroderma</keyword>
  <keyword>proton pump inhibitor</keyword>
  <keyword>alginic acid</keyword>
  <keyword>omeprazole</keyword>
  <keyword>prokinetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Scleroderma, Localized</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Domperidone</mesh_term>
    <mesh_term>Alginic acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Omeprazole Plus Alginic Acid and Placebo of Domperidone</title>
          <description>Alginic acid: Algycon 1 tab chew tid after meal
placebo (for domperidone): placebo (for domperidone) 1 tab oral tid before meal</description>
        </group>
        <group group_id="P2">
          <title>Omeprazole Plus Domperidone and Placebo of Alginic Acid</title>
          <description>Domperidone: domperidone (10 mg) 1 tab oral tid before meal
placebo (of alginic acid): placebo (for alginic acid) 1 tab chew tid after meal</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Omeprazole Plus Alginic Acid and Placebo of Domperidone</title>
          <description>Alginic acid: Algycon 1 tab chew tid after meal
placebo (for domperidone): placebo (for domperidone) 1 tab oral tid before meal</description>
        </group>
        <group group_id="B2">
          <title>Omeprazole Plus Domperidone and Placebo of Alginic Acid</title>
          <description>Domperidone: domperidone (10 mg) 1 tab oral tid before meal
placebo (of alginic acid): placebo (for alginic acid) 1 tab chew tid after meal</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="37"/>
            <count group_id="B2" value="38"/>
            <count group_id="B3" value="75"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.6" spread="9.5"/>
                    <measurement group_id="B2" value="46.7" spread="12.5"/>
                    <measurement group_id="B3" value="48.9" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Thailand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changing Severity of Heart Burn of SSc Related Omeprazole Resistant GERD Evaluated by Visual Analogue Score (VAS)</title>
        <description>VAS scale 0-100 was applied for an outcome measurement of the severity of heart burn. The VAS scale 0 was no symptoms of heart burn and scale 100 was a maximum symptom of heart burn. The changing of the severity of heart burn was the changing of VAS before and after treatment.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omeprazole Plus Alginic Acid and Placebo of Domperidone</title>
            <description>Alginic acid: Algycon 1 tab chew tid after meal
placebo (for domperidone): placebo (for domperidone) 1 tab oral tid before meal</description>
          </group>
          <group group_id="O2">
            <title>Omeprazole Plus Domperidone and Placebo of Alginic Acid</title>
            <description>Domperidone: domperidone (10 mg) 1 tab oral tid before meal
placebo (of alginic acid): placebo (for alginic acid) 1 tab chew tid after meal</description>
          </group>
        </group_list>
        <measure>
          <title>Changing Severity of Heart Burn of SSc Related Omeprazole Resistant GERD Evaluated by Visual Analogue Score (VAS)</title>
          <description>VAS scale 0-100 was applied for an outcome measurement of the severity of heart burn. The VAS scale 0 was no symptoms of heart burn and scale 100 was a maximum symptom of heart burn. The changing of the severity of heart burn was the changing of VAS before and after treatment.</description>
          <units>VAS (100)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9" spread="13.1"/>
                    <measurement group_id="O2" value="17.2" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changing of the Severity of Regurgitation</title>
        <description>VAS scale 0-100 was applied for an outcome measurement of the severity of regurgitation. The VAS scale 0 was no symptoms of regurgitation and scale 100 was a maximum symptom of regurgitation. The changing of the severity of regurgitation was the changing of VAS before and after treatment.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omeprazole Plus Alginic Acid and Placebo of Domperidone</title>
            <description>Alginic acid: Algycon 1 tab chew tid after meal
placebo (for domperidone): placebo (for domperidone) 1 tab oral tid before meal</description>
          </group>
          <group group_id="O2">
            <title>Omeprazole Plus Domperidone and Placebo of Alginic Acid</title>
            <description>Domperidone: domperidone (10 mg) 1 tab oral tid before meal
placebo (of alginic acid): placebo (for alginic acid) 1 tab chew tid after meal</description>
          </group>
        </group_list>
        <measure>
          <title>Changing of the Severity of Regurgitation</title>
          <description>VAS scale 0-100 was applied for an outcome measurement of the severity of regurgitation. The VAS scale 0 was no symptoms of regurgitation and scale 100 was a maximum symptom of regurgitation. The changing of the severity of regurgitation was the changing of VAS before and after treatment.</description>
          <units>VAS (100)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.9" spread="15.9"/>
                    <measurement group_id="O2" value="23.1" spread="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changing of Frequency of Symptoms in SSc Related Omeprazole Resistant GERD Evaluated by Frequency Scale for the Symptoms of GERD (FSSG)</title>
        <description>Unit scale 0-48 was applied for an outcome measurement of the frequency of symptoms. The unit scale 0 was no symptom and scale 48 was usual symptom of GERD. The changing of the frequency of symptoms was the changing of the unit scale before and after treatment.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omeprazole Plus Alginic Acid and Placebo of Domperidone</title>
            <description>Alginic acid: Algycon 1 tab chew tid after meal
placebo (for domperidone): placebo (for domperidone) 1 tab oral tid before meal</description>
          </group>
          <group group_id="O2">
            <title>Omeprazole Plus Domperidone and Placebo of Alginic Acid</title>
            <description>Domperidone: domperidone (10 mg) 1 tab oral tid before meal
placebo (of alginic acid): placebo (for alginic acid) 1 tab chew tid after meal</description>
          </group>
        </group_list>
        <measure>
          <title>Changing of Frequency of Symptoms in SSc Related Omeprazole Resistant GERD Evaluated by Frequency Scale for the Symptoms of GERD (FSSG)</title>
          <description>Unit scale 0-48 was applied for an outcome measurement of the frequency of symptoms. The unit scale 0 was no symptom and scale 48 was usual symptom of GERD. The changing of the frequency of symptoms was the changing of the unit scale before and after treatment.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="3.3"/>
                    <measurement group_id="O2" value="4.7" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>the Prevalence of Omeprazole-resistant GERD in SSc After 4 Weeks Treatment With Omeprazole</title>
        <time_frame>4 weeks</time_frame>
        <population>The number of analysed patients came out the total number of screening patients in the trial. The patients who were defined as omeprazole-resistant GERD were enrolled and randomized for either alginic acid plus placebo or domperidone plus placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Systemic Sclerosis With GERD (Before Randomization)</title>
            <description>omeprazole 20 mg bid ac for 4 weeks for overall systemic sclerosis with GERD</description>
          </group>
        </group_list>
        <measure>
          <title>the Prevalence of Omeprazole-resistant GERD in SSc After 4 Weeks Treatment With Omeprazole</title>
          <population>The number of analysed patients came out the total number of screening patients in the trial. The patients who were defined as omeprazole-resistant GERD were enrolled and randomized for either alginic acid plus placebo or domperidone plus placebo group.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59" lower_limit="51" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changing of the Quality of Life Which is Evaluated by EQ-5DTM</title>
        <description>VAS scale 0-100 was applied for an outcome measurement of the quality of life. The VAS scale 0 was the worst quality of life and scale 100 was the best quality of life. The changing of the quality of life was the changing of VAS of quality of life before and after treatment.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omeprazole Plus Alginic Acid and Placebo of Domperidone</title>
            <description>Alginic acid: Algycon 1 tab chew tid after meal
placebo (for domperidone): placebo (for domperidone) 1 tab oral tid before meal</description>
          </group>
          <group group_id="O2">
            <title>Omeprazole Plus Domperidone and Placebo of Alginic Acid</title>
            <description>Domperidone: domperidone (10 mg) 1 tab oral tid before meal
placebo (of alginic acid): placebo (for alginic acid) 1 tab chew tid after meal</description>
          </group>
        </group_list>
        <measure>
          <title>Changing of the Quality of Life Which is Evaluated by EQ-5DTM</title>
          <description>VAS scale 0-100 was applied for an outcome measurement of the quality of life. The VAS scale 0 was the worst quality of life and scale 100 was the best quality of life. The changing of the quality of life was the changing of VAS of quality of life before and after treatment.</description>
          <units>VAS (100)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.7" spread="15.8"/>
                    <measurement group_id="O2" value="76.1" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Omeprazole Plus Alginic Acid and Placebo of Domperidone</title>
          <description>Alginic acid: Algycon 1 tab chew tid after meal
placebo (for domperidone): placebo (for domperidone) 1 tab oral tid before meal</description>
        </group>
        <group group_id="E2">
          <title>Omeprazole Plus Domperidone and Placebo of Alginic Acid</title>
          <description>Domperidone: domperidone (10 mg) 1 tab oral tid before meal
placebo (of alginic acid): placebo (for alginic acid) 1 tab chew tid after meal</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>nausea</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title vocab="soft tissue infectio">soft tissue infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="leg pain">leg pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr.Chingching Foocharoen</name_or_title>
      <organization>Khon Kaen University</organization>
      <phone>6643363746</phone>
      <email>fching@kku.ac.th</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

